Monitor for definitive acquisition agreements or financing updates. The $100M revenue target is highly aspirational given the $49M market cap and pre-revenue status.
Price Chart
Executive Summary
Tevogen Bio announced a healthcare services initiative exploring potential acquisitions of a Management Services Organization (MSO) and a Contract Research Organization (CRO), targeting approximately $100 million in combined annual revenue. The company also reported Q4 2025 EPS of -$1.45, a 28.9% beat vs. consensus, though revenue remained at $0. The initiative is exploratory and non-binding, with no definitive agreements in place.
Key Financial Metrics
Key Facts
- William Keane appointed interim head of new healthcare services initiative.
- Evaluating potential acquisitions of an MSO and a CRO with ~$100M combined annual revenue target.
- Q4 2025 EPS reported at -$1.45, beating consensus estimate by 28.9%.
- Revenue remains $0; company is pre-revenue with no approved products.
- No definitive agreements have been signed; acquisitions are exploratory.
- Market cap is ~$49M; the ~$100M revenue target is aspirational and contingent on execution.
Financial Impact
EPS beat of 28.9% on a -$1.45 actual vs. consensus; revenue remains $0. Potential MSO/CRO acquisitions target ~$100M annual revenue, but no deal certainty.
Risk Factors
- Acquisitions may not materialize; no definitive agreements in place.
- Company is pre-revenue with no approved products; cash burn risk.
- Dilution risk if financing is needed for acquisitions.
- Regulatory and execution risks in healthcare services expansion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309293 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $6.72 | awaiting T+60 | — | $6.53 (−2.83%) |
Sep 16, 2026 5w ago | SC 13D/A | $7.71 | awaiting T+60 | — | $6.53 (−15.30%) |
Sep 16, 2026 5w ago | SC 13D/A | $7.71 | awaiting T+60 | — | $6.53 (−15.30%) |
Sep 16, 2026 5w ago | 8-K | $7.71 | awaiting T+60 | — | $6.53 (−15.30%) |
Jun 26, 2026 17w ago | EFFECT | $7.00 $7.43 | ▼ −6.14% | ▼ −1.66% | $6.53 (+6.71%) |
Jun 12, 2026 19w ago | S-3 | $10.02 $7.34 | ▲ +26.75% | ▲ +27.75% | $6.53 (+34.83%) |
Jun 9, 2026 19w ago | Press Release | $10.75 $7.17 | ▼ −33.30% | ▼ −37.12% | $6.53 (−39.26%) |
May 28, 2026 21w ago | Press Release | $8.04 $6.75 | ▼ −16.04% | ▼ −17.78% | $6.53 (−18.78%) |
May 21, 2026 22w ago | Press Release | $11.57 $6.58 | ▼ −43.10% | ▼ −47.40% | $6.53 (−43.54%) |
Mar 25, 2026 30w ago | Press Release | $5.18 $9.79 | ▲ +88.90% | ▲ +75.44% | $6.53 (+26.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers